Gilead Sciences Surpasses Expectations with Strong Q2 Earnings, Driven by HIV Treatment Success
Gilead Sciences Inc. reports strong Q2 2025 performance, exceeding market estimates with a net income of $1.9 billion and revising its 2025 guidance upwards due to its successful HIV treatment sales.
3 minutes to read